AU2001283451A1 - Methods and compositions for treating igE-related disease using NNT-1 inhibitors - Google Patents

Methods and compositions for treating igE-related disease using NNT-1 inhibitors

Info

Publication number
AU2001283451A1
AU2001283451A1 AU2001283451A AU8345101A AU2001283451A1 AU 2001283451 A1 AU2001283451 A1 AU 2001283451A1 AU 2001283451 A AU2001283451 A AU 2001283451A AU 8345101 A AU8345101 A AU 8345101A AU 2001283451 A1 AU2001283451 A1 AU 2001283451A1
Authority
AU
Australia
Prior art keywords
nnt
binding agent
ige
selective binding
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283451A
Other languages
English (en)
Inventor
Giorgio Senaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2001283451A1 publication Critical patent/AU2001283451A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001283451A 2000-08-18 2001-08-17 Methods and compositions for treating igE-related disease using NNT-1 inhibitors Abandoned AU2001283451A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22643600P 2000-08-18 2000-08-18
US60/226,436 2000-08-18
US09/931,704 US6849260B2 (en) 2000-08-18 2001-08-16 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
US09/931,704 2001-08-16
PCT/US2001/025906 WO2002015977A2 (en) 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors

Publications (1)

Publication Number Publication Date
AU2001283451A1 true AU2001283451A1 (en) 2002-03-04

Family

ID=26920541

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001283451A Abandoned AU2001283451A1 (en) 2000-08-18 2001-08-17 Methods and compositions for treating igE-related disease using NNT-1 inhibitors
AU2005232321A Abandoned AU2005232321A1 (en) 2000-08-18 2005-11-14 Methods and compositions for treating IgE-related disease using NNT-1-inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005232321A Abandoned AU2005232321A1 (en) 2000-08-18 2005-11-14 Methods and compositions for treating IgE-related disease using NNT-1-inhibitors

Country Status (7)

Country Link
US (1) US6849260B2 (cg-RX-API-DMAC7.html)
EP (1) EP1309374A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004513081A (cg-RX-API-DMAC7.html)
AU (2) AU2001283451A1 (cg-RX-API-DMAC7.html)
CA (1) CA2419274A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001434A (cg-RX-API-DMAC7.html)
WO (1) WO2002015977A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT787491E (pt) 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
DE69633623T2 (de) 1995-07-17 2005-12-01 Medivir Uk Ltd. Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
ATE273391T1 (de) 1997-02-03 2004-08-15 Amgen Inc Neurotrophischer faktor nnt-1
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
EP1001982A1 (en) 1997-06-30 2000-05-24 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
GB9913327D0 (en) 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
EP1309374A2 (en) 2003-05-14
US6849260B2 (en) 2005-02-01
AU2005232321A1 (en) 2005-12-01
WO2002015977A3 (en) 2002-11-28
MXPA03001434A (es) 2004-12-13
CA2419274A1 (en) 2002-02-28
US20020041873A1 (en) 2002-04-11
JP2004513081A (ja) 2004-04-30
WO2002015977A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ES2257739T3 (es) Antigenos ctla-8 de primate purificados y reactivos relacionados.
US7101689B2 (en) Interleukin-18 binding proteins, their preparation and use
US20090280082A1 (en) Methods for treating autoimmune disorders
US20030166862A1 (en) Purified mammalian CTLA-8 antigens and related reagents
PL180125B1 (pl) Bialko fuzyjne o swoistosci wiazania przeciwko ludzkiej IL-4, PL PL PL PL PL PL
JP2010213702A (ja) インターロイキン−１７関連哺乳動物サイトカイン、それをコードするポリヌクレオチド、使用
US20030021764A1 (en) Methods of treatment of neurological diseases by interferon antagonists
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
JP4864278B2 (ja) 脱髄疾患を処置する方法
US6676939B2 (en) Methods of modulating IL-174 response
AU2001288286A1 (en) Methods for treating demyelinating diseases
US6849260B2 (en) Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
TWI879859B (zh) 急性期之視神經脊髓炎之預防或治療劑
US6824781B2 (en) Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist
JP2002514067A (ja) 神経栄養因子ｎｎｔ−１
US20040219149A1 (en) Methods for the modulation of il-13
US20040096446A1 (en) Methods for treating demyelinating diseases
US12409208B2 (en) Treating tissue fibrosis with interleukin 24
MXPA06006377A (es) Metodos para modular la actividad de citocina y reactivos relacionados.
AU2007201935A1 (en) Methods for treating demyelinating disease
HK1135028A (en) Trkb agonists for treating autoimmune disorders